Puma Biotechnology Inc (PBYI)
Nasdaq: PBYI · Pharmaceutical Preparations · Los Angeles, CA · filing with the SEC since 2007
Grade6.2
◀ Past 5.8● Present 7.6▶ Future 4.7
Who owns Puma Biotechnology Inc
As filed with the SECHolders of 5% or more
3
Alan H. Auerbach holds 16% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D/A filed Oct 6, 2026 says.
Directors and officers
10
report now, of 20 people on the record since 2011. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Alan H. Auerbach
SCHEDULE 13D/A · filed Oct 6, 2026 · Common Stock, par value $0.0001 per share
Anders Hove
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.0001 par value per share · 6.7% in Nov 14, 2024
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Millennium Management LLC
SCHEDULE 13G/A · filed Feb 3, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
Camber Capital Management LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Frazier Life Sciences Public Fund, L.P.
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock · reported falling below 5%
What PBYI reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
17sales
0purchases
16sales on a scheduled plan
10people selling
$2.1Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window10 of 25 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Auerbach Alan H | President and CEO | 3 | $600,000 | 3 | 0 | $0 |
| Cesano Alessandra | director | 1 | $600,000 | 1 | 0 | $0 |
| Moyes Jay M | director | 1 | $200,000 | 1 | 0 | $0 |
| Senderowicz Adrian | director | 1 | $200,000 | 1 | 0 | $0 |
| Hunt Douglas M | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | 3 | $100,000 | 3 | 0 | $0 |
| Nougues Maximo F | Chief Financial Officer | 3 | $100,000 | 3 | 0 | $0 |
| Wilson Troy Edward | director | 2 | $100,000 | 2 | 0 | $0 |
| Dorval Allison | director | 1 | $100,000 | 1 | 0 | $0 |
| Miller Michael Patrick | director | 1 | $100,000 | 0 | 0 | $0 |
| Stuglik Brian M | director | 1 | $100,000 | 1 | 0 | $0 |